For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary brain delivery technology, the xB3³ platform, transports medicine across the blood-brain barrier to offer a more successful treatment for diseases of the central nervous system. We take a look at their tech, their stock price and financials. Tune in!
Latest News
Top 5 Gainers and Losers: KASH.CN, QIMC.CN, TGH.V
Zentek (ZEN.V) took a years long path to figure out its incredible biotech potential
Tesla stock to $100?
Top 5 Gainers and Losers: KASH.CN, DHR.V, BRO.V
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO
